Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes. - Wikidata - wikimedia - TriplyDB

Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.

Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.

http://www.wikidata.org/entity/Q30253045

about

Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.

http://www.wikidata.org/entity/Q30253045

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Lixisenatide reduces glycaemic ...... patients with type 2 diabetes.

@ast

Lixisenatide reduces glycaemic ...... patients with type 2 diabetes.

@en

type

label

Lixisenatide reduces glycaemic ...... patients with type 2 diabetes.

@ast

Lixisenatide reduces glycaemic ...... patients with type 2 diabetes.

@en

prefLabel

Lixisenatide reduces glycaemic ...... patients with type 2 diabetes.

@ast

Lixisenatide reduces glycaemic ...... patients with type 2 diabetes.

@en

P1433

Q30253045-D72665A1-6E3C-4A0D-A49D-EA00E9A4A592

P1476

Q30253045-CDF1B25B-1542-4A9D-ACB4-FED7F9C071D0

P2093

Q30253045-128D0AA8-20CA-4176-A632-B9DBFBBC0326

Q30253045-2D4EC349-F318-4635-992F-CA1B5388F8CF

Q30253045-72C38E08-F144-45BE-ACD1-8966342B3F0F

Q30253045-7FB24B49-9993-4DD0-8730-24A81AE8FD9F

Q30253045-9B2FC1F4-1651-401B-92C7-D701D2B6172A

Q30253045-E464BA06-F090-4C95-9603-E4A4AF58FA9E

Q30253045-E8996F2E-0612-4261-8320-7439A5A92E0F

P2860

Q30253045-013596D3-925B-4D02-8060-8CAB8C03ACA6

Q30253045-36AD0173-B771-4174-8120-6AC985EA8602

Q30253045-3FC7455D-E88A-452D-BF98-FAE8E60CEB4D

Q30253045-74891FBC-071A-4E19-9220-E485BA5031A2

Q30253045-AAD0810A-8F9B-4F90-9254-C992DA504511

Q30253045-AB259631-B188-4CBF-8675-5A46AA53A6C5

Q30253045-AF240C73-BE5B-4658-91C8-440D72AB5735

Q30253045-B68B3F15-4504-47F2-89B7-30DBCEBA12F8

Q30253045-BBC00CE5-A24D-4A8C-8449-67805D80078F

Q30253045-C22B390D-D94B-42DF-A451-D7B61B94EE83

P304

Q30253045-A3C5F382-5AE5-4921-973A-A3748E4A0E43

P31

Q30253045-C7AAB58A-EE6D-4C36-A5D7-866F6842BE28

P356

Q30253045-01B0357A-946B-4E26-BDEB-0A8E8E9D2CE5

P433

Q30253045-76A1BFD1-0545-4759-9087-DF333BA0486C

P478

Q30253045-B3C2EE46-E2F2-4543-BA17-85F09829DDC2

P50

Q30253045-73B3EB13-7694-4E5E-9615-1A356D6FF0B4

Q30253045-ADC91CF0-01BD-4475-9954-C63292D53337

P577

Q30253045-F0E57131-D32F-451A-B3F6-312BE808AA20

P698

Q30253045-3332C661-955B-4FE3-A99C-F62A0400CB50

P921

Q30253045-71AC4CCC-083F-4401-B6A8-79B08DC9376E

P356

P1433

Diabetes, Obesity and Metabolism

P1476

Lixisenatide reduces glycaemic ...... patients with type 2 diabetes

@en

P2093

Andres DiGenio

http://www.w3.org/2001/XMLSchema#string

Boris Kovatchev

http://www.w3.org/2001/XMLSchema#string

David O'Neal

http://www.w3.org/2001/XMLSchema#string

Eric Hernandez-Triana

http://www.w3.org/2001/XMLSchema#string

Eric Renard

http://www.w3.org/2001/XMLSchema#string

Jay Lin

http://www.w3.org/2001/XMLSchema#string

Ronald Goldenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Glycemic Variability: How Do We Measure It and Why Is It Important?

Sensitivity of Traditional and Risk-Based Glycemic Variability Measures to the Effect of Glucose-Lowering Treatment in Type 2 Diabetes Mellitus

How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes?

Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability

Visit-to-visit variability of fasting plasma glucose as predictor of ischemic stroke: competing risk analysis in a national cohort of Taiwan Diabetes Study.

The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c.

Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus.

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

P304

1317-1321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12930

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Cheol-Young Park

Guillermo E Umpierrez

P577

2017-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28256054

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes